文献速递治疗药物监测与药物基因组学特殊人群用药药物相互作用

茄啶衍生CYP2D6表型分析揭示老年多重用药患者表型转化

Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients.
PubMed 文献 · Br J Clin Pharmacol · 2025-01-01

本研究在88例老年多重用药患者中,利用饮食来源的茄啶代谢物SSDA和4-OH-茄啶作为CYP2D6生物标志物进行表型分析,并与基因型预测的活性评分比较。在调整年龄、性别、共病指数和eGFR的模型中,每增加一种CYP2D6底物/抑制剂,功能性变异患者的预期活性评分降低0.53分(95%CI 0.85-0.21)。表明饮食衍生生物标志物可揭示老年患者的表型转化。

要点

  • SSDA/茄啶代谢比与CYP2D6基因型活性评分显著相关,可识别弱代谢者。
  • 每增加一种CYP2D6底物/抑制剂,功能性变异患者活性评分降低0.53分。
  • 饮食衍生生物标志物可用于老年多重用药患者CYP2D6表型转化评估。

核心结论

  • 测量饮食来源的CYP2D6生物标志物可揭示老年多重用药患者的表型转化。

研究设计与样本

  • 在老年多重用药患者中收集血样和用药数据,用液相色谱-串联质谱测定茄啶及其代谢物进行CYP2D6表型分析,并行基因分型计算活性评分。
  • 共纳入88例有完整用药记录的患者,中位年龄83岁(IQR 77-87),女性占70.5%(n=62),中位用药15种(IQR 12-17)。

主要发现

  • 在调整年龄、性别、Charlson共病指数和eGFR的模型中,每增加一种CYP2D6底物/抑制剂,功能性变异患者的预期活性评分降低0.53分(95%CI 0.85-0.21),R2=0.242。

临床怎么用

  • 对于老年多重用药患者,可考虑使用饮食衍生的CYP2D6生物标志物评估表型转化,辅助个体化用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Phenoconversion, a genotype-phenotype mismatch, challenges a successful implementation of personalized medicine. The aim of this study was to detect and determine phenoconversion using the solanidine metabolites 3,4-seco-solanidine-3,4-dioic acid (SSDA) and 4-OH-solanidine as diet-derived cytochrome P450 2D6 (CYP2D6) biomarkers in a geriatric, multimorbid cohort with high levels of polypharmacy. METHODS: Blood samples and data of geriatric, multimedicated patients were collected during physician counsel (CT: NCT05247814). Solanidine and its metabolites were determined via liquid chromatography/tandem mass spectrometry and used for CYP2D6 phenotyping. CYP2D6 genotyping was performed and activity scores (AS) were assigned. Complete medication intake was assessed. A shift of the AS predicted via genotyping as measured by phenotyping was calculated. RESULTS: Solanidine and its metabolites were measured in 88 patients with complete documentation of drug use. Patients had a median age of 83 years (interquartile range [IQR] 77-87) and the majority (70.5%, n = 62) were female. Patients took a median of 15 (IQR 12-17) medications. The SSDA/solanidine metabolic ratio correlated significantly with the genotyping-derived AS (P < .001) and clearly detected poor metabolizers. In the model adjusted for age, sex, Charlson Comorbidity Index and estimated glomerular filtration rate each additional CYP2D6 substrate/inhibitor significantly lowered the expected AS by 0.53 (95% confidence interval 0.85-0.21) points in patients encoding functional CYP2D6 variants (R2 = 0.242). CONCLUSIONS: Phenotyping of CYP2D6 activity by measurement of diet-derived biomarkers elucidates phenoconversion in geriatric patients. These results might serve as a prerequisite for the validation and establishment of a bedside method to measure CYP2D6 activity in multimorbid patients for successful application of personalized drug prescribing.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sarömba JA, Müller JP, Tupiec J, et al. Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. Br J Clin Pharmacol. 2025. PMID: 40441673. doi:10.1111/bcp.70004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。